During the past decade, UCT Lung Institute conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 10 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 8 clinical trials were completed. i.e. 61.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCT Lung Institute" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Global Alliance for TB Drug Development" with 4 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "AIDS Clinical Trials Group" with 2 trials sponsored and "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCT Lung Institute" #1 collaborator was "University of Cape Town Lung Institute" with 3 trials as a collaborator, "European and Developing Countries Clinical Trials Partnership (EDCTP)" with 2 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "Statens Serum Institut" with 2 trials as a collaborator and "All India Institute of Medical Sciences, New Delhi" with 1 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "UCT Lung Institute" are "Tuberculosis" (9 trials), "Asthma" (4 trials), "Idiopathic Pulmonary Fibrosis" (4 trials), "Pulmonary Disease, Chronic Obstructive" (3 trials) and "Pulmonary Tuberculosis" (2 trials). Many other conditions were trialed in "UCT Lung Institute" in a lesser frequency.

Most popular intervention types in "UCT Lung Institute" are "Drug" (24 trials), "Biological" (5 trials), "Device" (4 trials), "Other" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Pyrazinamide" (4 trials), "Moxifloxacin" (3 trials), "PA-824" (3 trials) and "C-Tb" (2 trials). Other intervention names were less common.

The vast majority of trials in "UCT Lung Institute" are 36 trials for "All" genders.

Currently, there are NaN active trials in "UCT Lung Institute". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in UCT Lung Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in UCT Lung Institute, 4 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".